Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BSI 060T

Next Previous
X
Search
Drug Profile

BSI 060T

Alternative Names: Anti-Siglec-15 monoclonal antibody; Anti-siglec15 monoclonal antibody - Biosion; BSI-060T; PYX-106

Latest Information Update: 25 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biosion
  • Developer Biosion; Pyxis Oncology
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Siglec-15 protein inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Solid tumours

Most Recent Events

  • 19 Dec 2024 Suspended - Phase-I for Solid tumours (Late-stage disease, Second-line therapy or greater) in Spain, Belgium, USA (IV)
  • 19 Dec 2024 Suspended - Preclinical for Solid tumours in China (Parenteral)
  • 19 Dec 2024 Pharmacokinetics, pharmacodynamics and adverse events data from a phase I trial in Solid tumours released by Pyxis Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top